Timothy J. O’Rourke

3.7k citations

34 papers · 962 indexed · h-index 15

Impact in

Oncology top 10%
- Lung Cancer Research Studies
- Cancer Treatment and Pharmacology
Hepatology top 10%
- Liver physiology and pathology

Papers in

Oncology 13
- Cancer Treatment and Pharmacology 4
- Lung Cancer Research Studies 3
Genetics 5
- Myeloproliferative Neoplasms: Diagnosis and Treatment 2

Co-authors: Howard A. Burris Polly E. Kintzel F. Anthony Greco John D. Hainsworth Ronald G. Steis Anthony A. Meluch Lisa H. Morrissey Daniel D. Von Hoff
Journals: Journal of Clinical Oncology (8 papers)Anti-Cancer Drugs (3 papers)Cancer (2 papers)American Journal of Hematology (2 papers)Molecular Cancer Therapeutics (1 paper)
Partner nations: United States France Belgium

In The Last Decade

Timothy J. O’Rourke

33 papers receiving 932 citations

Peers

Countries citing papers authored by Timothy J. O’Rourke

Since Specialization

Citations

This map shows the geographic impact of Timothy J. O’Rourke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timothy J. O’Rourke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timothy J. O’Rourke more than expected).

Fields of papers citing papers by Timothy J. O’Rourke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timothy J. O’Rourke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timothy J. O’Rourke. The network helps show where Timothy J. O’Rourke may publish in the future.

Co-authors

The 25 scholars most cited alongside Timothy J. O’Rourke, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Timothy J. O’Rourke Line = papers co-authored together Timothy J. O’Rourke links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A phase 1 study of ALX148, a CD47 blocker, alone and in combination with established anticancer antibodies in patients with advanced malignancy and non-Hodgkin lymphoma. Journal of Clinical Oncology ·Nehal J. Lakhani, Patricia LoRusso, Navid Hafez, Anuradha Krishnamurthy, Timothy J. O’Rourke, Manali Kamdar, Philip Fanning, Yonggang Zhao, Feng Jin, Hong Wan, Jaume Pons, Sophia Randolph, Wells A. Messersmith	2018	14
2	Macrovascular Lesions Underlying Spontaneous Intracerebral Hemorrhage Seminars in Neurology ·Jacky T. Yeung, Branden Cord, Timothy J. O’Rourke, Renee M. Maina, Samuel Sommaruga, Charles Matouk	2016	3
3	Phase II Trial to Evaluate Gemcitabine and Etoposide for Locally Advanced or Metastatic Pancreatic Cancer Molecular Cancer Therapeutics ·Marianne K. Melnik, Craig P. Webb, Patrick J. Richardson, Charles R. Luttenton, Alan Campbell, Thomas Monroe, Timothy J. O’Rourke, Kathleen J. Yost, Connie M. Szczepanek, Michelle R. Bassett, Kimberly J. Truszkowski, Phyllis K. Stein, Matthew W. Van Brocklin, Alan T. Davis, Gabriela Bedolla, George F. Vande Woude, Han-Mo Koo	2010	14
4	Cost savings from dose rounding of biologic anticancer agents in adults Journal of Oncology Pharmacy Practice ·Brenda J Winger, Elizabeth Clements, Jaculin L. DeYoung, Timothy J. O’Rourke, Deborah L Claypool, Steve Vachon, Thomas H. VanDyke, Jennifer Zimmer‐Young, Polly E. Kintzel	2010	35
5	Increased Risk of Metabolic Syndrome, Diabetes Mellitus, and Cardiovascular Disease in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Polly E. Kintzel, Sandra L. Chase, Lisa Schultz, Timothy J. O’Rourke	2008	83
6	PD3-3-7: Safety and Pharmacokinetics (PK) of AMG 706 With Carboplatin/Paclitaxel (C/P) and/or Panitumumab for the treatment of patients with advanced non-small cell lung cancer (NSCLC) Journal of Thoracic Oncology ·George R. Blumenschein, Alan Sandler, Timothy J. O’Rourke, Jesse McGreivy, Yu‐Nien Sun, Yining Ye, Mandy Parson, Joe Stephenson	2007	7
7	Paclitaxel and Gemcitabine Chemotherapy for Advanced Transitional-Cell Carcinoma of the Urothelial Tract: A Phase II Trial of the Minnie Pearl Cancer Research Network Journal of Clinical Oncology ·Anthony A. Meluch, F. Anthony Greco, Howard A. Burris, Timothy J. O’Rourke, Gregory L. Ortega, Ronald G. Steis, Lisa H. Morrissey, Valerie Johnson, John D. Hainsworth	2001	155
8	Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: A phase II trial Annals of Oncology ·S. Fields-Jones, Alan J. Koletsky, G. Wilding, Mark Allen O’Rourke, Timothy J. O’Rourke, John R. Eckardt, Barbara B. Yates, C. McGuirt, Howard A. Burris	1999	48
9	Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignancies Investigational New Drugs ·Howard A. Burris, Éric Raymond, Ahmad Awada, John G. Kuhn, Timothy J. O’Rourke, James Brentzel, William R. Lynch, Shang‐Ying P. King, Thomas D. Brown, Daniel D. Von Hoff	1998	17
10	Expectations and experiences of patients with cancer participating in phase I clinical trials. PubMed ·Linda H. Yoder, Timothy J. O’Rourke, Annette Etnyre, Danielle Tavernier Spears, T.D. Brown	1997	48
11	Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea American Journal of Hematology ·James L. Furgerson, Svetislava J. Vukelja, W. Jeffrey Baker, Timothy J. O’Rourke	1996	29
12	Mixed-Lineage Acute Myeloid Leukemia Associated with a Suprasellar Dysgerminoma American Journal of Clinical Oncology ·Robert F. Krywicki, Karen Bowen, Lawrence L. Anderson, D E Garland, Patrick Cobb, Terry R. Jenkins, Timothy J. O’Rourke	1995	5
13	A randomized trial of two schedules of trimetrexate versus 5-fluorouracil in advanced colorectal cancer Anti-Cancer Drugs ·Thomas D. Brown, Thomas R. Fleming, Phyllis J. Goodman, John S. Macdonald, Reginald P. Pugh, Timothy J. O’Rourke	1995	7
14	Phase I trial of sulofenur (LY186641) given orally on a daily × 21 schedule Anti-Cancer Drugs ·Thomas D. Brown, Timothy J. O’Rourke, John G. Kuhn, Johnny B. Craig, Kathleen A. Havlin, Howard A. Burris, John Cagnola, J Michael Hamilton, Gerald B. Grindey, W. Satterlee, Daniel D. Von Hoff	1994	7
15	Prolonged, alternating chemotherapy for extensive small cell lung cancer. A southwest oncology group study Cancer ·Robert B. Livingston, Tove Thompson, John J. Crowley, Stephen K. Williamson, Frederick J. Meyers, Timothy J. O’Rourke, John R. Neefe	1993	3
16	Extended administration of oral etoposide and oral cyclophosphamide for the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. Journal of Clinical Oncology ·Steven M. Grunberg, John Crowley, Robert B. Livingston, Indrani Gill, Stephen K. Williamson, Timothy J. O’Rourke, T. Braun, M. Ernest Marshall, James K. Weick, S P Balcerzak	1993	9
17	Testicular relapse in adult acute myelogenous leukemia Cancer ·Don W. Shafer, Howard A. Burris, Timothy J. O’Rourke	1992	11
18	A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days Anti-Cancer Drugs ·James G. Wall, Howard A. Burris, Daniel D. Von Hoff, Gladys Rodriguez, Rayna Kneuper-Hall, Don W. Shaffer, Timothy J. O’Rourke, Thomas D. Brown, Geoffrey R. Weiss, Gary M. Clark, Shirley McVea, Randall S. Johnson, Carl J. Friedman, Brian R. Smith, William S Mann, John G. Kuhn	1992	106
19	Hemophagocytic syndrome: A cause of pancytopenia in human ehrlichiosis American Journal of Hematology ·Kevin C. Abbott, Svetislava J. Vukelja, Craig J. Smith, C. Kenneth McAllister, Keith A. Konkol, Timothy J. O’Rourke, Cynthia J. Holland, Miodrag Ristic	1991	40
20	Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390). PubMed ·Carlos L. Arteaga, T.D. Brown, J. Kuhn, H S Shen, Timothy J. O’Rourke, K Beougher, H. J. Brentzel, Daniel D. Von Hoff, Geoffrey R. Weiss	1989	52

About Timothy J. O’Rourke

Timothy J. O’Rourke is a scholar working on Oncology, Genetics, Hematology, Pulmonary and Respiratory Medicine and Neurology, having authored 34 papers that have together received 962 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (4 papers), Prostate Cancer Treatment and Research (3 papers), Lung Cancer Research Studies (3 papers), Lung Cancer Treatments and Mutations (3 papers), Neuroendocrine Tumor Research Advances (3 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (2 papers), Acute Myeloid Leukemia Research (2 papers) and Renal cell carcinoma treatment (2 papers). The work is most often cited by research in Oncology (345 citations), Hepatology (66 citations), Hematology (89 citations), Genetics (77 citations) and Occupational Therapy (28 citations). Timothy J. O’Rourke has collaborated with scholars based in United States, France and Belgium. Frequent co-authors include Howard A. Burris, Polly E. Kintzel, F. Anthony Greco, John D. Hainsworth, Ronald G. Steis, Anthony A. Meluch, Lisa H. Morrissey, Daniel D. Von Hoff, T.D. Brown and Geoffrey R. Weiss. Their work appears in journals such as Journal of Clinical Oncology, Anti-Cancer Drugs, Cancer, American Journal of Hematology and Molecular Cancer Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact